Mylan-Biocon’s insulin biosimilar faces FDA hurdle Industry-The Economic Times — June 2, 2018 comments off Firms have been asked to share details about a change in the manufacturing site for glargine from Bengaluru to a new facility in Malaysia.
Firms have been asked to share details about a change in the manufacturing site for glargine from Bengaluru to a new facility in Malaysia.